首页> 外文期刊>British Journal of Clinical Pharmacology >Differences in risk factors for anticoagulant-related nephropathy between warfarin and direct oral anticoagulants: Analysis of the Japanese adverse drug event report database
【24h】

Differences in risk factors for anticoagulant-related nephropathy between warfarin and direct oral anticoagulants: Analysis of the Japanese adverse drug event report database

机译:抗凝血相关肾病危险因素危险因素与直染生抗凝血剂抗凝血有关的肾病:日本不利药物事件报告数据库的分析

获取原文
获取原文并翻译 | 示例
           

摘要

Limited information is available on anticoagulant-related nephropathy (ARN). We therefore reviewed the Japanese Adverse Drug Event Report database to investigate kidney injury (KI) in patients administered warfarin or direct oral anticoagulants (DOACs) and sought to clarify the risk factors for ARN. KI risk in warfarin users was associated with male sex (odds ratio [OR], 1.70; 95% confidence interval [CI], 1.35-2.13; P = 80 years (OR, 1.35; 95% CI, 1.07-1.72; P = .01). KI risk in DOAC users was associated with body weight >= 80 kg (OR, 1.60; 95% CI, 1.01-2.53; P = .04) and use of dabigatran (OR, 1.61; 95% CI, 1.09-2.37; P < .01). Our findings suggest that risk factors for ARN differ between warfarin and DOACs and that these risk factors may be associated with bleeding risk. Therefore, the risk of ARN may be decreased by better managing bleeding risk in patients taking anticoagulants.
机译:关于抗凝剂相关肾病(ARN)的信息有限。因此,我们回顾了日本药物不良事件报告数据库,以调查服用华法林或直接口服抗凝剂(DOAC)的患者的肾损伤(KI),并试图阐明ARN的风险因素。华法林使用者的KI风险与男性相关(优势比[OR],1.70;95%可信区间[CI],1.35-2.13;P=80岁(OR,1.35;95%可信区间,1.07-1.72;P=0.01)。DOAC使用者的KI风险与体重>=80kg(OR,1.60;95%可信区间,1.01-2.53;P=.04)和达比加群的使用(OR,1.61;95%可信区间,1.09-2.37;P<.01)有关。我们的研究结果表明,在华法林和DOAC之间,ARN的风险因素不同,这些风险因素可能与出血风险有关。因此,通过更好地管理服用抗凝剂患者的出血风险,可以降低ARN的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号